SLC1A2 and schizophrenia: Schizophrenia patients display distinctive IgG glycosylation alterations, characterized by increased circulating IgG levels, the presence of a pro-inflammatory IgG receptor in the midbrain, and reduced glycosylation of glutamate transporters EAAT1 and EAAT2 in the prefrontal cortex, along with altered gene expression related to IgG N-glycan biosynthesis [28].